Jump to a section
- What is KPV?
- Why researchers study it
- Benefits discussed in literature
- Uses discussed in research
- Mechanisms discussed in published studies
- Reported study designs and protocol examples
- Protocol table from cited sources
- Limitations and research gaps
- Documentation checklist
- Related research supplies
- More KPV research
- Sources and references
Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.
This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.
Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.
This article summarizes findings from reviewed preclinical studies that examine the tripeptide Lys‑Pro‑Val (KPV), a C‑terminal fragment of α‑melanocyte‑stimulating hormone, focusing on reported effects, proposed mechanisms, and example experimental protocols described in the reviewed sources.
What is KPV?
KPV (Lys‑Pro‑Val) is a tripeptide corresponding to the C‑terminal sequence of α‑melanocyte‑stimulating hormone and has been studied as an anti‑inflammatory/neuroimmunomodulatory fragment of that peptide. [S5] [S6]
Why researchers study it
Researchers investigate KPV because fragments of α‑MSH including KPV have been implicated in modulation of inflammatory signaling (including NF‑κB), and because KPV has shown activity in experimental models of skin inflammation and pollutant injury, hepatic lipid accumulation, and intestinal inflammation—making it of interest for diverse tissue‑targeted applications. [S5] [S1] [S3] [S7] [S8]
Additional research interest arises from KPV’s utility as a targeting or cargo moiety in diagnostic probes and delivery systems (for example PepT1‑targeted imaging and liposomal or nanoparticle carriers) in preclinical models of colitis and pigment/autoimmune skin disease. [S6] [S7] [S4]
Benefits discussed in literature
In human HaCaT keratinocyte models and a 3D skin model, KPV treatment (50 µg/mL in the reported experiment) restored cell viability after PM10 exposure, reduced IL‑1β secretion, inhibited reactive oxygen species (ROS), reduced activation of ERK and p38 MAPK, decreased expression of apoptosis‑related proteins, and suppressed NF‑κB–mediated inflammatory signaling and caspase‑1 activation, suggesting mitigation of PM10‑induced keratinocyte death and inflammation. [S1]
In hepatic epithelial (HepG2) cells, KPV (100 µg/mL in the reported experiment) attenuated oleic acid–induced lipid accumulation, suppressed fatty acid synthase (FAS) expression, reduced ROS generation, prevented ERK activation, downregulated AKT phosphorylation, inhibited mTORC1 phosphorylation, and modulated PPARγ phosphorylation associated with lipogenesis. [S3]
In preclinical colitis models and related delivery studies, KPV delivered via nanoparticles or captured in a mucoadhesive hydrogel improved inflammatory and histologic parameters in rodent models of colitis, aided recovery of the epithelial mucosal barrier, and altered gut microbiota composition toward increased beneficial organisms in treated animals. [S7] [S8]
KPV has also been used as a targeting moiety in a fluorescent probe to exploit PepT1 overexpression in colonic epithelial cells for imaging and discrimination of chronic versus acute ulcerative colitis in experimental systems. [S6]
In a melanocyte/mouse model of vitiligo, KPV‑modified deformable liposomes carrying Nlrp3 shRNA were used to achieve melanocyte‑specific NLRP3 knockdown and significantly alleviated vitiligo development in that experimental system. [S4]
Uses discussed in research
KPV has been evaluated as a protective or therapeutic candidate in preclinical models of pollutant‑induced skin inflammation and cell death, with suggested applications in skin‑protective treatments and functional cosmetics based on in vitro and 3D skin model results. [S1]
KPV has been explored as a regulator of hepatocellular lipid accumulation in cell culture models, with proposed relevance to early stages of non‑alcoholic fatty liver disease (steatosis) in preclinical research. [S3]
KPV has been developed for colonic/rectal delivery in rodent models of inflammatory bowel disease using nanoparticle and hydrogel platforms to target inflamed mucosa and prolong local retention, and has been used as an imaging targeting unit for PepT1‑based fluorescent probes in epithelial models. [S7] [S8] [S6]
KPV has been employed as a surface modification of deformable liposomes to enable delivery of genetic cargo (Nlrp3 shRNA) for melanocyte‑targeted knockdown in a vitiligo model. [S4]
Mechanisms discussed in published studies
Multiple reviewed studies report that KPV reduces reactive oxygen species (ROS) generation, and several downstream effects are attributed to this antioxidant action—examples include prevention of ERK and p38 MAPK activation in keratinocytes and prevention of ERK activation in HepG2 cells. [S1] [S3]
KPV‑associated suppression of NF‑κB signaling and preservation of IκBα (a known mechanism of α‑MSH fragments) has been described as part of its anti‑inflammatory actions in reviewed literature. [S5] [S1]
In hepatic cells, KPV was associated with downregulation of AKT phosphorylation, inhibition of mTORC1 phosphorylation, and regulation of PPARγ phosphorylation that corresponded with reduced FAS expression and lowered lipid accumulation under oleic acid challenge. [S3]
In keratinocyte models, KPV reduced caspase‑1 activation and IL‑1β secretion consistent with inhibition of pyroptotic inflammatory cell death in response to particulate matter exposure. [S1]
For colitis applications, reviewed delivery platforms exploit PepT1‑mediated peptide uptake (for imaging) or mucosa‑adhesive hydrogel retention and controlled release (for therapeutic delivery); reported in vivo efficacy in rodent models is linked to local delivery, reduced oxidative stress, and restoration of epithelial barrier function. [S6] [S7] [S8]
In the vitiligo model, KPV‑modified liposomes were used as a delivery vehicle to achieve targeted genetic knockdown of Nlrp3 in melanocytes, and alleviation of disease was observed after NLRP3 reduction in that experimental system. [S4]
Reported study designs and protocol examples
Examples below summarize experimental details reported in the reviewed excerpts; only details explicitly present in those excerpts are listed.
Protocol table from cited sources
The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.
| Source | Study Type | Model / Subject | Amount Reported | Route Reported | Frequency | Duration | Notes |
|---|---|---|---|---|---|---|---|
| [S1] | Journal Article | Human HaCaT keratinocytes (and a 3D skin model) | 50 μg/mL | in vitro (cell culture treatment) | not reported in the reviewed source | not reported in the reviewed source | KPV restored viability after PM10 exposure, reduced IL‑1β, inhibited ROS, decreased ERK/p38 activation and apoptosis markers, suppressed NF‑κB and caspase‑1 activation; also attenuated inflammatory cell death in a 3D skin model. |
| [S3] | Journal Article | HepG2 hepatic epithelial cells | 100 µg/mL | in vitro (cell culture treatment) | not reported in the reviewed source | not reported in the reviewed source | KPV attenuated oleic acid–induced lipid accumulation, suppressed FAS expression, reduced ROS, prevented ERK activation, downregulated AKT phosphorylation, inhibited mTORC1 phosphorylation, and regulated PPARγ phosphorylation. |
| [S6] | Journal Article | Caco‑2 cell model (in vitro imaging studies) | not reported in the reviewed source | in vitro (cell exposure to DCM‑KPV probe) | not reported in the reviewed source | not reported in the reviewed source | DCM‑KPV fluorescent probe uses KPV to target PepT1 on colonic epithelial cells; probe enabled receptor‑targeted intracellular accumulation and imaging to distinguish chronic versus acute colitis models in experimental systems. |
| [S7] | Journal Article | Mouse model of dextran sodium sulfate (DSS)‑induced colitis; Caco2‑BBE in vitro assays | not reported in the reviewed source | colon‑targeted delivery via alginate‑chitosan hydrogel encapsulation of KPV‑loaded nanoparticles (NP‑KPV) | not reported in the reviewed source | not reported in the reviewed source | NPs (~400 nm) released KPV at inflamed colon sites; NP‑KPV reduced LPS‑induced inflammatory responses in Caco2‑BBE cells and protected mice from inflammatory and histologic parameters in DSS colitis; authors report similar efficacy with NP delivery at markedly lower KPV concentration versus free peptide. |
| [S8] | Journal Article | Rat TNBS‑induced ulcerative colitis model | not reported in the reviewed source | intracolonic (rectal) administration of PMSP‑KPV hydrogel | not reported in the reviewed source | not reported in the reviewed source | PMSP hydrogel adhered to inflamed colonic mucosa, captured and stabilized KPV, improved epithelial barrier recovery, modulated gut microbiota, and improved colitis outcomes in treated rats; mechanism associated with inhibition of oxidative stress. |
| [S4] | Journal Article | Melanocyte‑targeted vitiligo mouse model (melanoma‑Treg‑induced vitiligo model) | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | KPV‑modified deformable liposomes (KPV‑Lipos) carrying Nlrp3 shRNA were used to achieve melanocyte‑specific NLRP3 knockdown and significantly alleviated vitiligo progression in this mouse model. |
Limitations and research gaps
- All reviewed evidence is preclinical (in vitro, cell culture, and rodent models); no human clinical trial results are reported in the reviewed sources.
- Many protocol details relevant to translational use (administration frequency, dosing regimens, long‑term safety, and human pharmacokinetics) are not reported in the reviewed excerpts.
- Delivery methods and formulations vary across studies (free peptide, nanoparticles, hydrogels, liposomes), which limits direct comparability of reported outcomes.
Documentation checklist
- Confirm which experimental model (cell line vs. animal species and disease model) is being cited before extrapolating findings.
- Verify PepT1 expression status when considering PepT1‑targeted approaches in intestinal models.
- Assess whether a delivery platform (NPs, hydrogel, liposomes) is required for local retention or protection of peptide in the chosen experimental context.
- Recognize that mechanistic claims in the reviewed literature are based on preclinical assays and may not translate directly to clinical outcomes.
Related research supplies
- Laboratory reagent labeling supplies and inventory sheets
- Cold‑chain temperature loggers and storage monitoring labels
- Sterile storage vials and sealed research reagent boxes (for preclinical sample storage)
- Non‑abrasive biosafety cabinet surface cleaning wipes and documentation logs
Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.
Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.
Case with accessory space
Qunclay 14-Slot Vial Travel Case
A 14-slot case with additional compartments that can support organized research-supply storage. Use only for compatible materials and documented workflows.
Electronics and screen care
iCloth 70% IPA Electronics Wipes
Lint-free wipes marketed for compatible screens and electronics, useful in documentation and equipment work areas.
Label-printer refill
Phomemo M110 White Replacement Labels
White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.
Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.
Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.
Sources and references
- [S1] Sung J, Ju SY, Park S, Jung WK, Je JY, Lee SJ. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.. Tissue & cell. 2025. PMID: 40073467. DOI: 10.1016/j.tice.2025.102837
- [S2] Berr AL, Wiese K, Dos Santos G, Koch CM, Anekalla KR, Kidd M. Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer.. Oncogene. 2023. PMID: 37161053. DOI: 10.1038/s41388-023-02703-9
- [S3] Lee JY, Lee J, Jung WK, Je JY, Lee SJ. Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells.. Cytotechnology. 2026. PMID: 42064835. DOI: 10.1007/s10616-026-00967-z
- [S4] Zeng K, Zhu Y, Han Z, Xiong S, Zhao Y, Xiao Z. NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development.. Cell death and differentiation. 2026. PMID: 40935835. DOI: 10.1038/s41418-025-01578-5
- [S5] Ichiyama T, Sato S, Okada K, Catania A, Lipton JM. The neuroimmunomodulatory peptide alpha-MSH.. Annals of the New York Academy of Sciences. 2000. PMID: 11268347. DOI: 10.1111/j.1749-6632.2000.tb05386.x
- [S6] Zeng M, Shao A, Li H, Tang Y, Li Q, Guo Z. Peptide Receptor-Targeted Fluorescent Probe: Visualization and Discrimination between Chronic and Acute Ulcerative Colitis.. ACS applied materials & interfaces. 2017. PMID: 28349696. DOI: 10.1021/acsami.7b00936
- [S7] Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.. Gastroenterology. 2010. PMID: 19909746. DOI: 10.1053/j.gastro.2009.11.003
- [S8] Zhao Y, Xue P, Lin G, Tong M, Yang J, Zhang Y. A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon.. Acta biomaterialia. 2022. PMID: 35245681. DOI: 10.1016/j.actbio.2022.02.039
Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.